Sleep, hypnotics and chronic obstructive pulmonary disease - 08/08/11
, Petra J.E. Vos a
, Frank J.J. van den Elshout a
, P.N. Richard Dekhuijzen b
, Marjo J.T. van de Ven a
, Yvonne F. Heijdra b 
Summary |
The quality of sleep is significantly compromised in many patients with chronic obstructive pulmonary disease (COPD) and may be further diminished when certain comorbidities are present. A reduced sleep quality is associated with daytime consequences like fatigue, psychiatric problems and an impaired quality of life.
Sleep induces physiologic alterations in respiratory function, which can become pathologic and may provoke or worsen hypoxemia and hypercapnia in COPD. Dyspnea, cough and excessive mucus production should be optimised to minimise causes for sleep disturbance. Pharmacological therapy may be helpful; sedatives like benzodiazepines and non-benzodiazepine benzodiazepine-receptor agonists (NBBRAs) are (equally) effective in improving sleep quality. Whether or not these hypnotics produce serious adverse respiratory effects during sleep, remains unclear due to opposing studies. Therefore, their use should be as short as possible.
Le texte complet de cet article est disponible en PDF.Abbreviation : COPD, DIMS, EDS, FEV1, FRC, FVC, GABA, HCVR, HVR, NBBRA, OSAS, PCO2, PO2, REM, SaO2, TST, Ve, Vi, V/Q
Keywords : Benzodiazepines, Breathing, Hypnotics, Non-benzodiazepine benzodiazepine-receptor agonist, Pulmonary disease, Chronic obstructive
Plan
Vol 102 - N° 6
P. 801-814 - juin 2008 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
